PCDH7

Across TCGA pan-cancer cohorts, PCDH7 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PCDH7 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PCDH7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PCDH7 expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

LUAD, COAD, and SARC are the cancer types where PCDH7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.230	0.667	.007	16	view →
COAD	DFS	Median	IV	0.028	0.496	<.001	15	view →
SARC	OS	Median	All	0.127	0.860	<.001	6	view →
LUSC	DFS	Median	III,IV	0.079	0.751	.024	6	view →
LIHC	DFS	Median	All	0.147	0.311	.032	5	view →
UCEC	DFS	Median	II,III,IV	0.922	0.440	.038	2	view →
HNSC	OS	Median	All	1.000	0.370	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PCDH7–LUAD (OS)

Open the LUAD breakdown →